Search Within

Rachel Nicole Grisham

Formats
  1. Journal Article (80)
  2. Meeting Abstract (78)
  3. Review (9)
  4. Guidelines (3)
  5. Book Section (2)
  6. Editorial (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (175)
  2. GDMT, Medicine (175)
  3. Gynecologic Medicine Service (175)
  4. Gynecology Disease Management Team (175)
  5. Solid Tumor Oncology Division (175)
  6. Surgery (76)

More Groups

People
  1. Carol Aghajanian (87)
  2. Roisin O'Cearbhaill (68)
  3. Alexia Iasonos (63)
  4. Qin Zhou (56)
  5. Dennis Chi (52)
  6. Kara Long Roche (49)

More People

Years
  1. 2025 (13)
  2. 2024 (29)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Gynecologic Oncology (49)
  2. Journal of Clinical Oncology (37)
  3. International Journal of Gynecological Cancer (28)
  4. Clinical Cancer Research (8)
  5. Cancer (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (50)
  2. American Society of Clinical Oncology (42)
  3. Lippincott Williams & Wilkins (30)
  4. American Association for Cancer Research (10)
  5. Wiley Blackwell (8)
  6. Nature Publishing Group (6)

More Publishers

Results (175)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Voices of women with low-grade serous ovarian cancer: Results from a multinational survey
    Meeting Abstract

    Sun, C.; Andrews, N.; Ludemann, J.; Larsen, E.; MacKay, C.; de Fazio, A.; Gaillard, S.; Gourley, C.; Carey, M.; Fader, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
    Meeting Abstract

    Grisham, R.; Monk, B.; Nieuwenhuysen, E.; Moore, K.; Fabbro, M.; O'Malley, D.; Oaknin, A.; Thaker, P.; Oza, A.; Colombo, N.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Folate receptor positivity in low-grade serous ovarian cancer: Exploring new therapeutic possibilities
    Meeting Abstract

    Manning-Geist, B.; Sullivan, M.; Zhou, Q.; Iasonos, A.; Stallworth, C.; Liu, Y.; Roche, K. L.; Gordhandas, S.; Chi, D.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer
    Meeting Abstract

    Colombo, N.; Van Gorp, T.; Matulonis, U.; Oaknin, A.; Grisham, R.; Provencher, D.; Fleming, G.; Olawaiye, A.; Pashova, H.; Tudor, I. C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Progression-free and overall survival in newly-diagnosed homologous recombination DNA-repair deficient ovarian cancer without a BRCA mutation
    Meeting Abstract

    Graves, S.; Sullivan, M.; Adkoli, A.; Zhou, Q.; Chi, D.; Ellenson, L.; O'Cearbhaill, R.; Weigelt, B.; Grisham, R.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 Part A
    Meeting Abstract

    Banerjee, S.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Clamp, A.; Ray-Coquard, I.; Chon, H. S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
    Meeting Abstract

    Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • High-grade serous carcinomas derived from low-grade serous neoplasms: Clinicopathological and molecular features and prognostic implications
    Meeting Abstract

    Kang, E. Y.; Long Roche, K.; Weigelt, B.; Grisham, R.; Chui, M. H.
    Laboratory Investigation (2024)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: Ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 3.2024
    Guidelines

    Liu, J.; Berchuck, A.; Backes, F. J.; Cohen, J.; Grisham, R.; Leath, C. A. 3rd; Martin, L.; Matei, D.; Miller, D. S.; Robertson, S.; more...
    Journal of the National Comprehensive Cancer Network (2024)

    Fulltext@MSK | Save
  • A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC)
    Meeting Abstract

    Jazaeri, A. A.; Grisham, R. N.; Gaillard, S.; How, J. A.; Hazard, S.; Musso, L.; Kyi, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save